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Abstract
Diagnostic delay is common in most respiratory diseases, particularly in bronchiectasis. However, sex bias in
diagnostic delay has not been studied to date. Objective: Assessment of diagnostic delay in bronchiectasis by sex.
Methods: The Spanish Historical Registry of Bronchiectasis recruited adults diagnosed with bronchiectasis from
2002 to 2011 in 36 centres in Spain. From a total of 2113 patients registered we studied 2099, of whom 1125
(53.6%) were women. Results: No differences were found for sex or age (61.0+ 20.6, p¼ 0.88) or for localization
of bronchiectasis (p¼ 0.31). Bronchiectasis of unknown aetiology and secondary to asthma, childhood infections
and tuberculosis was more common in women (all ps < 0.05). More men than women were chronic obstructive
pulmonary disease-related bronchiectasis and colonized by Haemophilus influenzae (p < 0.001 for both). Onset of
symptoms was earlier in women. The diagnostic delay for women with bronchiectasis was 2.1 years more than for
men (p ¼ 0.001). Discussion: We recorded a substantial delay in the diagnosis of bronchiectasis. This delay was
significantly longer in women than in men (>2 years). Independent factors associated with this sex bias were age at
onset of symptoms, smoking history, daily expectoration and reduced lung function.
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Introduction
Bronchiectasis is a condition involving irreversible
dilation of the bronchi and bronchioles as a conse-
quence of the destruction of the elastic and muscular
component of the bronchial wall. Bronchiectasis can
be the outcome of many disorders that harm bronchial
defence mechanisms and produce damage including
alteration/imbalance in the mucociliary system, reten-
tion of secretions, and bacterial colonization. Bron-
chial colonization, in turn, results in release of
inflammatory mediators that worsen ciliary motility
and cause recurrent infections, thus closing the
vicious circle that perpetuates the disease and leads
to tissue damage.1
Data on the prevalence of bronchiectasis in the
general population are scanty, with estimates varying
from 25 to 272 cases per 100,000 individuals. Most of
this variability is likely explained by age.2–5 How-
ever, prevalence is often underestimated for various
reasons: the difficulty in differentiating between
bronchiectasis and other chronic respiratory diseases,
the fact that symptoms are progressive and unspecific
during the early stages of the condition (bronchiecta-
sis is clinically evident when the disease is exacer-
bated or very severe6), unawareness of the term
bronchiectasis among the general population, and the
absence/limitations of imaging studies in patients
with chronic respiratory diseases. These factors often
lead to delays in diagnosis.
Chronic conditions increase in number as the pop-
ulation ages. Moreover, the availability of HRCT has
facilitated diagnosis. Therefore, the prevalence of
bronchiectasis is expected to rise considerably in the
future.
Diagnostic delay, or the time between onset of
symptoms and clinical diagnosis, is common in many
chronic diseases and particularly in respiratory condi-
tions. Epidemiological studies in chronic obstructive
pulmonary disease (COPD) have illustrated the high
rate of underdiagnosis in mild to severe stages7; these
findings led to strategies targeting an earlier diagnosis
to minimize the social and healthcare impact of
COPD.8 The only study on diagnostic delay in
bronchiectasis to date concluded that the delay could
be as long as 17 years.9 Despite the relevance of this
delay, contributing factors have not been reported.
Sex bias occurs when, for whatever reason and in
equal diagnostic opportunities, one of the sexes is
systematically belatedly diagnosed with a medical
event in comparison with the other one. Sex bias has
been reported in the diagnosis of cystic fibrosis (CF)
in the United States, with girls diagnosed 4 months
later than boys.10 No publications to date have ana-
lysed sex bias in adults diagnosed with bronchiectasis.
The aim of our study was to determine clinical
differences in the diagnosis of bronchiectasis by sex
in order to quantify diagnostic delay and to assess sex
bias and its determinants.
Methods
The Spanish Historical Registry of Bronchiectasis is
an anonymous multicentre prospective registry that
gathered information from 2002 to 2011 in adults with
bronchiectasis who were diagnosed based on the find-
ings in HRCT, CT, bronchography or chest X-ray and
clinical presentation. All the included patients diag-
nosed using X-ray had CF. The study population was
recruited during a stable phase of the disease from 36
centres in 11 Spanish Autonomous Communities.
When the registry opened in 2002, there was no
requirement to request clinical consent for inclusion
in the registry. However, all patients were informed
that they would not be identified and would remain
anonymous. Informed consent was explained orally
and obtained from all participants who were identified
and followed up from respiratory departments, not
from primary care.
Recruiting physicians were instructed to follow
standardized clinical and diagnostic recommenda-
tions for the inclusion of patients and collection of
their data. These recommendations were later
included in Spanish Society of Pulmonology and
Thoracic Surgery’s National Guidelines on Diagnosis
and Treatment of Bronchiectasis, which were pub-
lished in 200811 and mainly follow the British Thor-
acic Society guideline for non-CF bronchiectasis.12
Aetiology was classified as post-infection (tuber-
culosis and childhood infections), bronchial obstruc-
tion, primary and secondary immune defect (human
immunodeficiency infection, haematological diseases
and transplants), mucociliary clearance disorders (CF,
primary ciliary dyskinesia and Young syndrome),
aspiration and inhalation injury, congenital and air-
way abnormality, allergic bronchopulmonary asper-
gillosis, associated with other diseases (connective
tissue diseases, asthma, COPD and inflammatory
bowel disease), and idiopathic.
The complete physical examination included cal-
culation of the body mass index (BMI), spirometry to
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evaluate forced vital capacity (FVC) and forced
expiratory volume in 1 s (FEV1) and radiography of
the paranasal sinuses.
A microbiological analysis of sputum was per-
formed at the first visit and then every 3–6 months
depending on the symptoms to confirm chronic bron-
chial infection. Initially, Gram and auramine staining
were conducted, and samples were subsequently cul-
tured for mycobacteria and fungi in blood agar, Mac-
Conkey agar and chocolate agar as well as in other
growth media. The patient was considered colonized
when the same microorganism was isolated in three
consecutive samples for a minimum of 1 month dur-
ing a 6-month period.
Bronchiectasis was assessed using CT and classi-
fied depending on the location of the clinical presen-
tation as follows: localized, bilateral (both lungs
affected) and diffuse (4 lobes affected, with the lin-
gula considered to be a separate lobe); and prevailing
type (cylindrical or cystic). Pulmonary function tests
were performed close in time to CT imaging.
The diagnostic delay in years was calculated as the
difference between the date of onset of symptoms and
the date of diagnosis. Age at onset was divided into
three groups: <20 years, 21–40 years, and >40 years.
Onset of symptoms was defined as persistent produc-
tion of mucopurulent sputum or at least one episode of
haemoptysis. Data were analysed for the individual
patient and by subgroups (with/without CF).
Statistical analysis
Dara were preprocessed in Microsoft Excel and then
imported into R 3.2.3. As this is a multicentre reg-
istry, study variables were first filtered before
ranges, outliers and errors were determined. After
discussion, some patients were excluded because of
major errors in one or more key variables, for exam-
ple, pulmonary function. Once data were filtered,
continuous variables were tested for normality using
the Kolmogorov–Smirnov test in order to continue
the analysis with either the usual parametric tests,
such as analysis of variance and the t test, or the
non-parametric tests. Quantitative variables were
expressed as mean + standard deviation; qualitative
variables were expressed as counts and percentage of
the total. Qualitative variables were compared using
the chi-square test.
Non-parametric tests were also used to analyse the
variable diagnostic delay, namely, the Fligner-Killeen
test for the analysis of the homogeneity of variances13
and the Wilcoxon–Mann–Whitney test for the com-
parison of populations by gender.
A linear multivariate model was also included,
with diagnostic delay as the dependent variable and
demographic and clinical variables that were signifi-
cant in the bivariate analysis as the independent vari-
ables. The threshold for selection of variables was
established using the Akaike information criterion
and a stepwise algorithm. A p < 0.05 was deemed
statistically significant.
Results
Of the 2113 patients recruited (Figure 1), 14 were
excluded because of errors during data collection.
Of the remaining 2099 patients (Figure 2), 1125
(53.6%) were women. There were no differences by
sex in the following variables: age, bronchodilator test
results, diagnostic test to determine bronchiectasis,
location, haemoptysis, sinusitis, or chronic bronchial
colonization with Pseudomonas aeruginosa (all p >
0.05; Table 1).
Men were more frequently smokers or smoked
more (p < 0.001), weighed more (p ¼ 0.010), and
expectorated yellow-green sputum more frequently
than women do (p < 0.04). Women had better pul-
monary function and oxygen saturation (SaO2) than
men did (p < 0.001). Hence, men expectorated darker
sputum, experienced haemoptysis, had chronic bron-
chial colonization with Haemophilus influenzae, and
died more frequently compared to women (18.6% vs.
10.2%, p < 0.001).
Bronchiectasis of unknown aetiology was the
most common type in both sexes (Table 2) and more
frequent in women (p < 0.001). It was also diagnosed
as secondary to asthma (p ¼ 0.007), infections in
childhood (p < 0.001), and tuberculosis (p ¼ 0.02).
COPD and CF were more frequent in men (p <
0.001). No differences by sex were observed for
treatment (Table 3).
The main analysis of diagnostic delay is presented
in Table 4. Onset of symptoms was earlier in women
(32.2 vs. 34.9 years, p ¼ 0.015) and age at diagnosis
was not significantly different between men and
women (45.5 vs. 46.0, p¼ 0.61). The diagnostic delay
in women was 2.1 years more than in men (p ¼
0.001). When individuals were analysed globally,
with and without the subgroup of patients with CF,
an effect of age on diagnostic delay was observed.
Accordingly, women had a diagnostic delay of 5 years
when onset was before age 20 years (21 vs. 16,
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p ¼ 0.001). This result was sustained when individu-
als with CF were excluded (22.2 vs. 25.7, p ¼ 0.03).
On the contrary, diagnostic delay was 1.3 years longer
in men than women when patients older than 40 years
were taken into consideration. This result also held
when CF was excluded (Table 4). When the analysis
was repeated after excluding 163 patients with
COPD, the difference in diagnostic delay between
men and women was also sustained (11.4 vs. 13.3 years,
p ¼ 0.009).
Finally, analysis of the independent effect of var-
ious demographic and clinical variables on explain-
ing diagnostic delay in bronchiectasis (Table 5)
revealed that the 2.1-year delay in women was sus-
tained and even increased to 4.5 years in the multi-
variate linear model. The variables confirmed as
independent factors accounting for this association
were higher BMI, lower FVC, smoking, characteris-
tics of sputum and early age at onset of symptoms
(all with p < 0.05).
Discussion
We present the first results from the study cohort of
the Spanish Historical Registry of Bronchiectasis,
which comprises more than 2000 patients, with
emphasis on differences by sex. We conclude that
there is a significant diagnostic delay in bronchiecta-
sis of 12 years and that this is considerably higher in
Figure 1. Geographical distribution of centres participating in the Spanish Historic Registry of Bronchiectasis: number of
patients with bronchiectasis enrolled by Autonomous Community.
Figure 2. STROBE (Strengthening the Reporting of Obser-
vational studies in Epidemiology) flowchart of participation in
the Spanish Historic Registry of Bronchiectasis.
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Table 1. Demographic and clinical characteristics of bronchiectasis patients.
Mean + SD/N (%) Overall (n ¼ 2099) Men (n ¼ 974) Women (n ¼ 1125) p value
Age 61.0 + 20.6 60.9 + 21.8 61.0 + 19.6 0.88
Smoking <0.001
Smoker 206 (9.8) 137 (14.1) 69 (6.1)
Former smoker 512 (24.4) 391 (40.2) 121 (10.8)
Non-smoker 1378 (65.7) 445 (45.7) 933 (83.1)
BMI 24.3 + 4.9 24.6 + 4.5 24.1 + 5.1 0.010
FVC (%) 70.0 + 19.8 66.5 + 19.7 73.1 + 19.4 <0.001
FEV1 (%) 64.8 + 24.5 58.3 + 24.5 70.5 + 23.1 <0.001
FEV1/FVC 68.6 + 15.2 64.3 + 16.1 72.5 + 13.2 <0.001
SaO2 94.8 + 4.0 94.2 + 4.3 95.3 + 3.5) <0.001
Bronchodilator test 0.23
Negative 907 (46.0) 426 (47.2) 481 (45.0)
Positive 522 (26.5) 222 (24.6) 300 (28.0)
Not performed 543 (27.5) 254 (28.2) 289 (27.0)
Diagnostic test for bronchiectasis 0.20
HRCT 1716 (81.9) 803 (82.4) 913 (81.4)
CT 304 (14.5) 129 (13.2) 175 (15.6)
Bronchography 14 (0.7) 7 (0.7) 7 (0.6)
Chest X-ray and clinical presentation 62 (3.0) 35 (3.6) 27 (2.4)
Location of bronchiectasis 0.31
Localized 527 (25.2) 258 (26.5) 269 (24.0)
Bilateral 946 (45.2) 424 (43.6) 522 (46.5)
Diffuse 622 (29.7) 291 (29.9) 331 (29.5)
Expectoration 0.04
No 299 (14.2) 119 (12.2) 180 (16.0)
Frequently 631 (30.1) 292 (30.0) 339 (30.1)
Daily 1169 (55.7) 563 (57.8) 606 (53.9)
Type of expectoration 0.02
White 611 (29.1) 298 (30.6) 313 (27.8)
White-yellow 701 (33.4) 315 (32.3) 386 (34.3)
Yellow-green 489 (23.3) 243 (24.9) 246 (21.9)
No 298 (14.2) 118 (12.1) 180 (16.0)
Haemoptysis 0.69
No 1393 (66.4) 656 (67.4) 737 (65.6)
Occasionally 618 (29.5) 280 (28.7) 338 (30.1)
Frequently 86 (4.1) 38 (3.9) 48 (4.3)
Sinusitis 0.12
n (%) 624 (29.7) 273 (28) 351 (31.2)
Chronic bronchial colonization 0.01
Occasional 51 (3.7) 20 (3.2) 31 (4.1)
Yes 807 (59.2) 393 (63.8) 414 (55.3)
No 247 (18.1) 106 (17.2) 141 (18.9)
No expectoration 259 (19.0) 97 (15.7) 162 (21.7)
CBC Hi <0.01
n (%) 234 (17.2) 132 (21.4) 102 (13.6)
CBC Pa 0.94
n (%) 500 (36.7) 227 (36.9) 273 (36.5)
Deaths <0.001
n (%) 258 (14.1) 157 (18.6) 101 (10.2)
SD: standard deviation; BMI: body mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; SaO2: oxygen
saturation; HRCT: high-resolution computed tomography; CBC: chronic bronchial colonization; Hi: Haemophilus influenzae; Pa: Pseu-
domonas aeruginosa.
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women (>2 years). The independent variables respon-
sible for this sex bias were age at onset of symptoms,
smoking, daily expectoration and poor pulmonary
function.
The delay in diagnosing bronchiectasis in women
was also related to COPD, perhaps because of differ-
ences in the presentation of symptoms (more dys-
pnoea in women and more expectoration in men) as
Table 2. Aetiology of bronchiectasis.
N (%) Overall (n ¼ 2099) Men (n ¼ 974) Women (n ¼ 1125) p value
Idiopathic
n (%) 506 (24.1) 189 (19.4) 317 (28.2) <0.001
Tuberculosis
n (%) 386 (18.4) 158 (16.2) 228 (20.3) 0.02
Cystic fibrosis
n (%) 282 (13.4) 154 (15.8) 128 (11.4) 0.004
Primary immunodeficiency
n (%) 215 (10.2) 114 (11.7) 101 (9) 0.05
Infections in childhood
n (%) 179 (8.5) 55 (5.6) 124 (11) <0.001
COPD
n (%) 164 (7.8) 147 (15.1) 17 (1.5) <0.001
Asthma
n (%) 123 (5.9) 42 (4.3) 81 (7.2) 0.007
Primary ciliary dyskinesia or Young syndrome
n (%) 67 (3.2) 35 (3.6) 32 (2.8) 0.39
Aspiration and inhalation injury
n (%) 55 (2.6) 24 (2.5) 31 (2.8) 0.78
Other
n (%) 51 (2.4) 22 (3.4) 18 (1.6) 0.012
Connective tissue disease
n (%) 43 (2) 14 (1.4) 29 (2.6) 0.09
Acquired immunodeficiency
n (%) 28 (1.3) 9 (0.9) 19 (1.7) 0.18
COPD: chronic obstructive pulmonary disease.
Table 3. Treatment.
Overall (n ¼ 2099) Men (n ¼ 974) Women (n ¼ 1125) p value
Oral antibiotics
(n ¼ 2013) (n ¼ 935) (n ¼ 1078) 0.07
No 1645 (81.7) 776 (83.0) 869 (80.6)
Continuous 77 (3.8) 26 (2.8) 51 (4.7)
Cyclic 291 (14.5) 133 (14.2) 158 (14.7)
Inhaled antibiotics
(n ¼ 1954) (n ¼ 911) (n ¼ 1043) 0.58
No 1586 (81.2) 731 (80.2) 855 (82.0)
Continuous 273 (14.0) 132 (14.5) 141 (13.5)
Periodic 95 (4.9) 48 (5.3) 47 (4.5)
Inhaled bronchodilators
(n ¼ 1986) (n ¼ 919) (n ¼ 1067) 0.08
n (%) 1519 (76.5) 720 (78.3) 799 (74.9)
Inhaled corticosteroids
(n ¼ 1961) (n ¼ 909) (n ¼ 1052) 0.55
n (%) 1336 (68.1) 626 (68.9) 710 (67.5)
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well as a predisposition among physicians to think
that COPD disproportionately affects men who were
called earlier for spirometry.14
The 4-month delay in diagnosing CF in girls com-
pared with boys reported by Lai et al.10 in a series of
patients in the United States (1986–1998) was asso-
ciated with more functional and nutritional deteriora-
tion and earlier acquisition of P. aeruginosa in
females. Implementation of neonatal screening
revealed earlier diagnosis of CF that improved nutri-
tional development and growth and thus minimized
deterioration of pulmonary function. This success
enabled interventions to be implemented earlier,
before further irreversible pulmonary damage. It also
enabled more aggressive treatment to be started at the
first isolation of P. aeruginosa and the microorganism
to be eradicated, thus modifying the natural history of
the disease and extending survival.15
A recent 3-year (2006–2008) prospective study of
189 patients with bronchiectasis from the northeast of
England revealed a diagnostic delay of 17 years for
both idiopathic and non-idiopathic disease.9 How-
ever, this analysis did not report differences by sex
or examined related factors.
Any delay in diagnosis of bronchiectasis holds up
initiation of treatment that might delay or prevent
disease progression. King et al.16 reported an average
annual loss in FEV1 of 50 ml more than in the general
population of the same age and sex, which is similar
to that observed in other respiratory conditions, such
as COPD. However, not all studies have reported this
loss. Factors associated with accelerated loss of pul-
monary function include systemic inflammation and
number of severe exacerbations.17 However, the fac-
tor most likely associated with the loss of pulmonary
function in bronchiectasis is colonization or chronic
infection with P. aeruginosa, although no causal rela-
tionship has been established to date between these
phenomena. Martı́nez-Garcı́a et al.18 observed that
patients who were chronically colonized by P.
Table 4. Diagnostic delay, by gender and CF, according to age onset of symptoms.
Mean + SD Overall (n ¼ 2099) Men (n ¼ 974) Women (n ¼ 1125) p value (t test)
Age at diagnosis 45.7 + 23.9 46.0 + 25.1 45.5 + 22.7 0.61
Age at symptoms onset 33.5 + 25.1 34.9 + 26.0 32.2 + 24.3 0.01
Diagnostic delay 12.2 + 15.5 11.1 + 14.0 13.2 + 16.6 0.001
All
<20 years at onset (n ¼ 825) 19 + 19.19 16 + 17.5 21 + 20.13 <0.001
20–40 years (n ¼ 411) 13.41 + 14 13.9 + 14.3 13.1 + 13.8 0.51
>40 years (n ¼ 863) 5.1 + 6.5 5.7 + 6.9 4.4 + 6.1 0.003
Only individuals with CF (n ¼ 282) (n ¼ 154) (n ¼ 128)
<20 years at onset (n ¼ 251) 7.2 + 12.4 6.23 + 10.6 8.43 + 14.5 0.18
20–40 years (n ¼ 22) 5.32 + 7.3 2.22 + 2.9 7.5 + 8.7 0.06
>40 years (n ¼ 9) 7.7 + 8.91 8 + 7.1 7.57 + 9.9 0.95
Only individuals without CF (n ¼ 1817) (n ¼ 820) (n ¼ 997)
<20 years at onset (n ¼ 574) 24.34 + 19.3 22.2 + 18.2 25.7 + 19.9 0.03
20–40 years (n ¼ 389) 13.9 + 14.2 14.6 + 14.4 13.4 + 14 0.40
>40 years (n ¼ 854) 5.04 + 6.5 5.7 + 6.9 4.4 + 6 0.003
SD: standard deviation; CF: cystic fibrosis.
Table 5. Multivariate linear regression model of factors
associated with diagnostic delay.
Dependent variable
Diagnostic delay (years)






Type of expectoration: white or
yellow
3.9a (1.3)
Type of expectoration: yellow or
green
4.5a (1.4)
Type of expectoration: none 0.04 (1.3)
Death 3.6b (1.4)
Age at onset of symptoms 0.3a (0.02)
Constant 30.8b (13.0)
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aeruginosa presented a 124-ml annual loss of FEV1
compared with only 30 ml in non-colonized patients.
Therefore, it is important to eradicate this bacter-
ium.11,12 Extrapolation of these data would indicate
that a diagnostic delay of 2 years in women could
produce a loss of up to 250 ml in FEV1 in patients
infected by P. aeruginosa, thus potentially leading to
frequent exacerbations.
Kapur and Karadag19 explored the differences and
similarities in paediatric patients with non-CF bronch-
iectasis and found that many children, despite having
symptoms during their first year of life, were not
diagnosed until much later, thus accumulating a diag-
nostic delay of 4–8 years, which is similar to that
found in countries with different socioeconomic lev-
els and healthcare facilities. In our series, we also
observed a longer diagnostic delay in women who
experienced onset of symptoms before age 20 years.
This delay decreased as respiratory symptoms subse-
quently appeared, probably because women could
have minimized their symptoms, as they would have
to endure bronchiectasis from an early age, and may
not have sought healthcare or could have been mis-
diagnosed for years.
Other clinical data that influenced diagnostic delay
were symptoms, mainly expectoration, smoking sta-
tus, and poor pulmonary function. Daily expectora-
tion and yellow-green sputum were more frequent in
men, probably because more men smoked and expec-
toration by women is less socially and culturally tol-
erated.20 Daily expectoration is a key symptom of
bronchiectasis and an indicator of the diagnosis.11,12
Previous smoking and its consequences, such as lung
cancer, oblige the clinician to request imaging studies
earlier. Therefore, in this sense, men could again be
diagnosed earlier than women.8 Likewise, better pul-
monary function in women might also influence diag-
nostic delay. The superior functional data in women
(FVC, FEV1, FEV1/FVC and SaO2) translated into a
milder clinical presentation and less need to seek
healthcare. However, this conclusion cannot be cor-
roborated in the absence of quality-of-life question-
naires or number of medical visits, neither of which
was available at the onset of this register. In addition,
the fact that patients are often vague about the origin
of their symptoms makes diagnosis challenging in the
sense that it is difficult to define when and how symp-
toms become clinically significant.
Bronchiectasis complicates other respiratory dis-
eases, increases hospital stay, requires costly treat-
ments, deteriorates quality of life, and is associated
with high health costs and substantial use of
resources.21,22 Establishing an earlier diagnosis
should enable initiation of treatment with reduced
morbidity, fewer exacerbations, and delayed chronic
bronchial colonization by P. aeruginosa. It should
also reduce the cost burden of the disease. Symptoms
should be recognized at the primary care level in order
to refer the patient to a specialist as soon as possible
and to start the path towards a differential diagnosis,
since HRCT and other tests are more widely available
nowadays.
Our study has both advantages and limitations.
With more than 2000 cases of bronchiectasis, the
sample size is sufficient for the main objective and
for the sensitivity analysis. Furthermore, with a
follow-up of over 10 years, it brings together a multi-
centre experience of 20,000 person-years. The inter-
nal quality control guaranteed the value and
usefulness of the data set, making it amongst the larg-
est available. As ours is a historical registry, it pro-
vides relevant information that will enable us to
explore the natural history of bronchiectasis and com-
pare our findings with those of subsequent series and
series reported elsewhere. Our registry is limited by
the fact that it was designed at the beginning of this
century. Current practice requires HRCT or broncho-
graphy before inclusion in a bronchiectasis registry;
hence, 3% of patients were diagnosed using thoracic
radiography only. Likewise, follow-up variables that
evaluate changes in the disease were not gathered
prospectively. The same is true of data on exacerba-
tions and hospitalizations, although mortality data
were collected. Finally, baseline assessment of dys-
pnoea using the mMRC (modified Medical Research
Council) or other scales limits the estimation of newly
available multicomponent indices such as BSI
(Bronchiectasis Severity Index)23 or FACED,24
although extrapolation of data can be explored.
Conclusions
This first analysis of the Spanish Historical Registry
of Bronchiectasis enabled us to explore sex differ-
ences in diagnostic delay in bronchiectasis. We found
a diagnostic delay of 12 years that was significantly
higher in women (>2 years vs. men). Age at symptom
onset, smoking habits, daily expectoration, and low
pulmonary function were identified as independent
explanatory factors of this sex bias and should be
evaluated in depth, given the implications of a delay
in diagnosing bronchiectasis.
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